December 20, 202007 3346

Staff Portfolio

Home / About Us / Staff Portfolio
  • Dmitry A. Ovchinnikov, PhD
    Dmitry A. Ovchinnikov, PhDScientific Director & General Manager

    Dmitry has a long record in molecular genetics, starting from some of the pioneering work on the mouse conditional genetics at the turn of the century, to more recent significant success with using the many forms of CRISPR/Cas9 technology to model normal development and disease in human pluripotent stem cells. In addition to that, Dmitry has a wealth of experience in generation and characterization of the induced pluripotent stem cell (iPSC) lines not only from humans cells, but also from many other mammals, including more exotic non-eutherian mammals. Using his expertise, the Core facility is expanding the range of offered services, and augment the comprehensive iPS generation and characterisation-related services with extensive range of CRISPR/Cas9-enabled and other advanced genome-manipulation technologies. Those will include genome editing (including the generation of large deletions  and seamless gene editing), as well as latest perivital genome visualization technologies.

  • Desi Veleva, PhD
    Desi Veleva, PhDLab Manager/Senior Research Assistant

    Dr Veleva completed her PhD at the National Centre for Adult Stem Cell Research at Griffith University in 2010. Her research background is on neurogenesis of the nervous system focusing primarily on working with adult stem cells derived from the olfactory system and the brain. She joined the Cancer and Ageing Research Program (CARP) at the Translational Research Institute and worked as a postdoctoral fellow on projects focusing in genomic instability and ageing, as well as chemotherapy resistance in lung cancer. Before joining the StemCARE team at the UQ AIBN, Desi worked as a clinical scientist in the Cancer Collaborative BioBank at Princess Alexandra Hospital where she gained invaluable knowledge and skills in Haematology and Blood Cancers. She joined StemCore team at the end of 2019, and applies her excellent organisational and experimental skills to running of our molecular biology pipeline.